These data led to the hypothesis that combination of poxvirus-based immunotherapy with dual PD plus LAG-3 checkpoint inhibition would result in a highly efficacious combination treatment regimen that would trigger a robust and unconstrained tumor-infiltrating antigen-specific T cell response. This evidence concerns the gene LAG3 and neoplasm.